PURPOSE: To determine whether a new formulated albuterol aerosol could sustain inhibition to bronchoconstriction for approximately one day in guinea pigs challenged with carbachol. METHODS: Large and porous particles, comprising a combination of endogenous or FDA-approved excipients and albuterol sulfate, were prepared by spray drying using a NIRO portable spray drier. The anesthetized animals inhaled 5 mg of large porous or small nonporous particles by forced ventilation via cannulae inserted in the lumen of their exposed tracheae. At regular intervals over a period of 36 hours after drug delivery, airway resistance was determined in response to carbachol challenge dose. RESULTS: Whereas inhalation of small nonporous albuterol particles protected from the carbachol-induced bronchoconstriction for up to 5 hours, inhalation of large porous albuterol particles produced a significant inhibition of carbachol-induced bronchoconstriction for at least 16 hours. CONCLUSIONS: The absence of substantial side effects, verified over a period of 24 hours by evaluating cardio-respiratory parameters as well as pulmonary inflammation, supports the utility of large porous albuterol particles for sustained therapies in asthma and other types of lung disease.
PURPOSE: To determine whether a new formulated albuterol aerosol could sustain inhibition to bronchoconstriction for approximately one day in guinea pigs challenged with carbachol. METHODS: Large and porous particles, comprising a combination of endogenous or FDA-approved excipients and albuterol sulfate, were prepared by spray drying using a NIRO portable spray drier. The anesthetized animals inhaled 5 mg of large porous or small nonporous particles by forced ventilation via cannulae inserted in the lumen of their exposed tracheae. At regular intervals over a period of 36 hours after drug delivery, airway resistance was determined in response to carbachol challenge dose. RESULTS: Whereas inhalation of small nonporous albuterol particles protected from the carbachol-induced bronchoconstriction for up to 5 hours, inhalation of large porous albuterol particles produced a significant inhibition of carbachol-induced bronchoconstriction for at least 16 hours. CONCLUSIONS: The absence of substantial side effects, verified over a period of 24 hours by evaluating cardio-respiratory parameters as well as pulmonary inflammation, supports the utility of large porous albuterol particles for sustained therapies in asthma and other types of lung disease.
Authors: D A Edwards; J Hanes; G Caponetti; J Hrkach; A Ben-Jebria; M L Eskew; J Mintzes; D Deaver; N Lotan; R Langer Journal: Science Date: 1997-06-20 Impact factor: 47.728
Authors: Rana M Obaidat; Bassam M Tashtoush; Mohammad F Bayan; Rana T Al Bustami; Mohammad Alnaief Journal: AAPS PharmSciTech Date: 2015-03-12 Impact factor: 3.246
Authors: Oleg V Evgenov; Daniel S Kohane; Kenneth D Bloch; Johannes-Peter Stasch; Gian P Volpato; Evangelia Bellas; Natalia V Evgenov; Emmanuel S Buys; Mark J Gnoth; Amanda R Graveline; Rong Liu; Dean R Hess; Robert Langer; Warren M Zapol Journal: Am J Respir Crit Care Med Date: 2007-09-13 Impact factor: 21.405